XML 15 R6.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited) - USD ($)
Preferred Stock
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Total Citius Pharmaceuticals, Inc. Shareholder’s Equity
Non-Controlling Interest
Total
Balance at Sep. 30, 2021 $ 145,979 $ 228,084,195 $ (96,047,821) $ 132,182,353 $ 600,380 $ 132,782,733
Balance (in Shares) at Sep. 30, 2021   145,979,429          
Issuance of common stock for services $ 50 95,834 95,884 95,884
Issuance of common stock for services (in Shares)   50,201          
Stock-based compensation expense 904,604 904,604 904,604
Net loss (9,225,220) (9,225,220) (9,225,220)
Balance at Dec. 31, 2021 $ 146,029 229,084,633 (105,273,041) 123,957,621 600,380 124,558,001
Balance (in Shares) at Dec. 31, 2021   146,029,630          
Balance at Sep. 30, 2021 $ 145,979 228,084,195 (96,047,821) 132,182,353 600,380 132,782,733
Balance (in Shares) at Sep. 30, 2021   145,979,429          
Net loss             (25,649,906)
Balance at Jun. 30, 2022 $ 146,129 231,287,208 (121,697,727) 109,735,610 600,380 110,335,990
Balance (in Shares) at Jun. 30, 2022   146,129,630          
Balance at Dec. 31, 2021 $ 146,029 229,084,633 (105,273,041) 123,957,621 600,380 124,558,001
Balance (in Shares) at Dec. 31, 2021   146,029,630          
Issuance of common stock for services $ 100 177,900 178,000 178,000
Issuance of common stock for services (in Shares)   100,000          
Stock-based compensation expense 1,020,998 1,020,998 1,020,998
Net loss (7,561,054) (7,561,054) (7,561,054)
Balance at Mar. 31, 2022   $ 146,129 230,283,531 (112,834,095) 117,595,565 600,380 118,195,945
Balance (in Shares) at Mar. 31, 2022   146,129,630          
Stock-based compensation expense   1,003,677 1,003,677 1,003,677
Net loss   (8,863,632) (8,863,632) (8,863,632)
Balance at Jun. 30, 2022 $ 146,129 231,287,208 (121,697,727) 109,735,610 600,380 110,335,990
Balance (in Shares) at Jun. 30, 2022   146,129,630          
Balance at Sep. 30, 2022 $ 146,211 232,368,121 (129,688,467) 102,825,865 600,380 103,426,245
Balance (in Shares) at Sep. 30, 2022   146,211,130          
Stock-based compensation expense 1,201,081 1,201,081 1,201,081
Net loss (3,593,645) (3,593,645) (3,593,645)
Balance at Dec. 31, 2022 $ 146,211 233,569,202 (133,282,112) 100,433,301 600,380 101,033,681
Balance (in Shares) at Dec. 31, 2022   146,211,130          
Balance at Sep. 30, 2022 $ 146,211 232,368,121 (129,688,467) 102,825,865 600,380 $ 103,426,245
Balance (in Shares) at Sep. 30, 2022   146,211,130          
Issuance of common stock upon exercise of stock options (in Shares)             46,667
Net loss             $ (22,599,002)
Balance at Jun. 30, 2023   $ 158,858 249,828,398 (152,287,469) 97,699,787 600,380 98,300,167
Balance (in Shares) at Jun. 30, 2023   158,857,798          
Balance at Dec. 31, 2022 $ 146,211 233,569,202 (133,282,112) 100,433,301 600,380 101,033,681
Balance (in Shares) at Dec. 31, 2022   146,211,130          
Issuance of common stock for services $ 100 101,900 102,000 102,000
Issuance of common stock for services (in Shares)   100,000          
Issuance of common stock upon exercise of stock options $ 47 31,220 31,267 31,267
Issuance of common stock upon exercise of stock options (in Shares)   46,667          
Stock-based compensation expense 1,165,595 1,165,595 1,165,595
Net loss (10,526,025) (10,526,025) (10,526,025)
Balance at Mar. 31, 2023 $ 146,358 234,867,917 (143,808,137) 91,206,138 600,380 91,806,518
Balance (in Shares) at Mar. 31, 2023   146,357,797          
Issuance of common stock in registered direct offering, net of costs of $1,201,131 $ 12,500 13,786,370 13,798,870 13,798,870
Issuance of common stock in registered direct offering, net of costs of $1,201,131 (in Shares)   12,500,001          
Stock-based compensation expense   1,174,111 1,174,111 1,174,111
Net loss   (8,479,332) (8,479,332) (8,479,332)
Balance at Jun. 30, 2023   $ 158,858 $ 249,828,398 $ (152,287,469) $ 97,699,787 $ 600,380 $ 98,300,167
Balance (in Shares) at Jun. 30, 2023   158,857,798